Mealtime-related dosing directions for proton-pump inhibitors in gastroesophageal reflux disease: Physician knowledge, patient adherence

Journal of the American Pharmacists Association

Volumn 54, Issue 2, 2014, Pages 144-153

  Solem, Caitlyn ^a   Mody, Reema ^b   Stephens, Jennifer ^a   Macahilig, Cynthia ^c   Gao, Xin ^a  

^a PHARMERIT INTERNATIONAL   (United States)

^b Takeda Pharmaceuticals International   (United States)

^c Medical Data Analytics   (United States)

Author keywords

Adherence; Gastroesophageal reflux disease; Patients; Physicians; Proton pump inhibitors; Survey

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; ARTICLE; FEMALE; GASTROENTEROLOGIST; GASTROESOPHAGEAL REFLUX; GENERAL PRACTITIONER; HEALTH CARE PERSONNEL; HUMAN; LIKERT SCALE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHARMACIST; PROFESSIONAL KNOWLEDGE; STOMACH PH; AGED; ATTITUDE TO HEALTH; CLINICAL PRACTICE; DRUG ADMINISTRATION; DRUG LABELING; FOOD; INFORMATION PROCESSING; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PATIENT EDUCATION; PHYSICIAN; STANDARDS; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ADULT; AGED; DATA COLLECTION; DRUG ADMINISTRATION SCHEDULE; DRUG LABELING; FEMALE; FOOD; GASTROESOPHAGEAL REFLUX; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; PHARMACISTS; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS; PROTON PUMP INHIBITORS; UNITED STATES;

EID: 84898847218     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/JAPhA.2014.13117     Document Type: Article

References (10)

1. DRUG-REAX System (electronic version). (n.d.). Thomson Reuters (Healthcare) Inc. http://www.rubali.com/new/index.php?option=com- content&view=article&id=9&Itemid=125. Accessed July 2011.
2. Lee RD, Vakily M, Mulford D, Wu J, Atkinson SN. Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor-evidence for dosing flexibility. Aliment Pharmacol Ther. 2009;29:824-833.
3. Gunaratnam NT, Jessup TP, Inadomi J, Lascewski DP. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2006;23:1473-1477.
4. Chey WD, Mody RR, Izat E. Patient and physician satisfaction with proton pump inhibitors (PPIs): are there opportunities for improvement? Dig Dis Sci. 2010;55:3415-3422.
5. Hatlebakk JG, Katz PO, Camacho-Lobato L, Castell DO. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther. 2000;14:1267-1272.
6. Ronis DL. Conditional health threats: health beliefs, decisions, and behaviors among adults. Health Psychol. 1992;11:127-134.
7. Lu L, Shara N. Reliability analysis: calculate and compare intra-class correlation coefficients (ICC) in SAS. Northeast SAS Users Group 2007;14. www.nesug.org/proceedings/nesug07/sa/sa13.pdf
8. Van Soest EM, Siersema PD, Dieleman JP, Sturkenboom MC, Kuipers EJ. Persistence and adherence to proton pump inhibitors in daily clinical practice. Aliment Pharmacol Ther. 2006;24:377-385. (Pubitemid 43972906)
9. Chey WD, Mody RR, Wu EQ, et al. Treatment patterns and symptom control in patients with GERD: US community-based survey. Curr Med Res Opin. 2009;25:1869-1878.
10. Hungin AP, Hill C, Molloy-Bland M, Raghunath A. Systematic review: patterns of proton pump inhibitor use and adherence in gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2011;10:109-116.